Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Inari Medical Inc (NARI)

Inari Medical Inc (NARI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Financial Summary for [[ item.sessionDateDisplayLong ]]
Inari Medical, Inc. is a commercial-stage medical device company committed toward developing products to treat and change the lives of patients suffering from venous diseases. Its initial product offering comprises 2 minimally-invasive, novel catheter-based mechanical thrombectomy devices. It built its products purposely on the basis of the specific characteristics of the venous system and the treatment of the two distinct indications of venous thromboembolism or VTE (deep vein thrombosis and pulmonary embolism/ PE). Its FlowTriever product is the first thrombectomy system, which is FDA-cleared, used for the treatment of PE. Its advanced systems & processes to control the key relationships between its sales representatives and treating physicians like cardiologists, radiologists, helps it to quickly iterate products, launch and execute physician education and training programs and scale its sales organization. The company markets and sells its products to hospitals across the U.S.

Fiscal Year End Date: 12/31

(Values in U.S. Thousands) Sep, 2024 Jun, 2024 Mar, 2024 Dec, 2023 Sep, 2023
Sales 153,390 145,820 143,190 132,090 126,370
Sales Growth +5.19% +1.84% +8.40% +4.53% +6.18%
Net Income -18,370 -31,350 -24,200 -4,670 3,160
Net Income Growth +41.40% -29.55% -418.20% -247.78% +51.20%
(Values in U.S. Thousands) Sep, 2024 Jun, 2024 Mar, 2024 Dec, 2023 Sep, 2023
Total Assets 697,240 672,930 661,780 674,240 548,840
Total Assets Growth +3.61% +1.68% -1.85% +22.85% +4.55%
Total Liabilities 262,480 249,120 214,550 209,330 96,690
Total Liabilities Growth +5.36% +16.11% +2.49% +116.50% +8.25%
(Values in U.S. Thousands) Sep, 2024 Jun, 2024 Mar, 2024 Dec, 2023 Sep, 2023
Operating Cash Flow 1,940 -780 -12,290 35,930 23,690
Operating Cash Flow Growth +348.72% +93.65% -134.21% +51.67% +205.68%
Net Cash Flow 2,000 30,980 28,000 -21,010 28,960
Change in Net Cash Flow -93.54% +10.64% +233.27% -172.55% +1,311.72%
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar